DANAHER CORP /DE/
Danaher (DHR) appoints Heathre Moler as Chief HR Officer effective 1 October 2026, replacing Georgeann Couchara. Moler has spent over a decade at Danaher. The company reported $24.6bn in 2025 revenue. Julie Sawyer Montgomery will also become CEO on the same date, succeeding Rainer Blair. Danaher recently acquired Masimo for $9.9bn and is pursuing StatLab.
MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.
Blair Rainer (President & CEO) sold 58,255 indirectly-held shares of DANAHER CORP /DE/ (DHR) at an average of $218.63 ($217.77–$219.35, $12.74M total) across 3 trades on 2026-08-21.
Over the past 7 days, alphai's AI scored 5 news stories mentioning DHR (DANAHER CORP /DE/). Coverage has skewed bullish: 3 bullish, 2 neutral, and 0 bearish.
Recent DHR coverage spans earnings, financial news and corporate actions.
In the last 30 days, DHR insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($12.7M). The most active reporter was Blair Rainer, President & CEO, with 3 filings.
Leadership change at the HR level may influence talent strategy and operational efficiency across Danaher's divisions.
Diversified exposure to life‑sciences tools may see incremental demand.
Large insider sell may signal confidence concerns, likely modest downward pressure.
Positive earnings beat and forward‑shifted revenue suggest near‑term revenue upside.
Positive earnings beat with solid bioprocessing order growth may support near‑term price appreciation.
alphai scores every news story that mentions DHR with an AI model for sentiment and relevance, and aggregates insider trades from DANAHER CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Danaher (DHR) appoints Heathre Moler as Chief HR Officer effective 1 October 2026, replacing Georgeann Couchara. Moler has spent over a decade at Danaher. The company reported $24.6bn in 2025 revenue. Julie Sawyer Montgomery will also become CEO on the same date, succeeding Rainer Blair. Danaher recently acquired Masimo for $9.9bn and is pursuing StatLab.
2 min readMRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.
3 min readBlair Rainer (President & CEO) sold 58,255 indirectly-held shares of DANAHER CORP /DE/ (DHR) at an average of $218.63 ($217.77–$219.35, $12.74M total) across 3 trades on 2026-08-21.
1 min readDanaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.
3 min readDanaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.
3 min readDanaher (DHR) shareholder Rainer M. Blair plans to sell 58,255 shares, valued at $12.7M, under Rule 144. The shares stem from restricted stock units awarded between 2020-2025. Danaher has 702.99M shares outstanding, listed on NYSE. The sale is scheduled for August 21, 2026, with Goldman Sachs as broker.
1 min readAn earnings-season recap of Danaher and other research tools and consumables firms’ Q2 results. The group’s revenues beat consensus by 1.7% and next-quarter guidance matched expectations. Danaher reported $6.27B revenue, up 5.5% YoY, beating analysts by 2.7%, and its stock was up 1.6% to $204.36. Other cited names include AVTR, BRKR, SHC, and TMO.
4 min readDanaher (DHR) reported Q2 2026 results with $6.3B revenue (+5.5% YoY), adj. EPS $1.94 (+8%), and raised full-year 2026 adj. EPS guidance to $8.45–$8.60, but its bioprocessing unit missed expectations. The move pressured Sartorius and Bio-Rad (BIO), which has a $5B strategic stake in Sartorius. Bio-Rad reported Q2 net sales $651M flat YoY and launched a restructuring with $80–$90M pre-tax charges.
4 min readThermo Fisher (TMO) and Danaher (DHR) both reported better-than-expected fiscal Q2 results. TMO said revenue rose 10% to $11.99B, GAAP diluted EPS to $4.68, and adjusted EPS to $6.03, and raised guidance. DHR showed improving core growth and high-single-digit adjusted EPS growth, with some revenue timing deferred. Hedge fund ownership rose for TMO but fell for DHR.
7 min readThe UN’s 2026 Sustainable Development Goals health report warns healthcare progress may stall as international funding declines. It says only 36% of 139 targets are on track or making moderate progress, while 49% move too slowly and 15% regressed. Separately, Danaher names Julie Sawyer Montgomery CEO in Oct 2026 and reaffirms 2026 guidance; Johnson & Johnson shifts leadership in Innovative Medicine; P&G expands Health Care after buying Thorne for $3.8bn; Heidi reports NHS AI adoption.
6 min read
